Lipella Pharmaceuticals Faces Delisting Concerns
Ticker: LIPO · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Lipella Pharma might get delisted, check their latest filings ASAP.
AI Summary
Lipella Pharmaceuticals Inc. filed an 8-K on June 20, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company's principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
Why It Matters
This filing indicates potential issues with Lipella Pharmaceuticals' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation as a publicly traded entity.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- June 20, 2025 (date) — Date of earliest event reported
- 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208 (location) — Registrant's principal executive office
- Delaware (location) — State of incorporation
FAQ
What specific listing rule or standard has Lipella Pharmaceuticals Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Lipella Pharmaceuticals Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 20, 2025.
What is the principal executive office address for Lipella Pharmaceuticals Inc.?
The principal executive office of Lipella Pharmaceuticals Inc. is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
What other items are included in this 8-K filing besides the delisting notice?
This 8-K filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
In which state was Lipella Pharmaceuticals Inc. incorporated?
Lipella Pharmaceuticals Inc. was incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding LIPELLA PHARMACEUTICALS INC. (LIPO).